United States Biotechnology & Medical Research

Adverum Biotechnologies Inc (ADVM)

Track

Adverum Biotechnologies Inc. experienced notable insider activity in December 2025. CEO Laurent Fischer and COO Peter Soparkar executed planned purchases, while Braden Michael Leonard conducted multiple sales. These transactions represent the most recent market movements, occurring over three months ago, reflecting varied individual portfolio adjustments among key leadership and stakeholders.
Ticker: ADVM Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Adverum Biotechnologies Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Planned buy 8 Dec 2025
Value US$4,410,062.35 | Price 359.40 | Shares 18,683 (+21.4%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2025-12-08 2025-12-08 PP Planned purchase
1.5
Fischer Laurent

CEO, PRESIDENT AND DIRECTOR

Executive Director
18,683 +21.4%
359.40
US$4,410,062 		18,683 +21.4% 359.40 US$4,410,062
2025-12-08 2025-12-05 PP Planned purchase
1.6
Soparkar Peter

CHIEF OPERATING OFFICER

Officer
97,700 -32.4%
208.43
US$4,016,037 		97,700 -32.4% 208.43 US$4,016,037
2025-12-08 2025-12-05 PP Planned purchase
1.5
Fischer Laurent

CEO, PRESIDENT AND DIRECTOR

Executive Director
66,731 +15.9%
103.51
US$1,732,609 		66,731 +15.9% 103.51 US$1,732,609
2025-12-05 2025-12-04 S Sale
2.9
Leonard Braden Michael
Large shareholder
524,560 -21.1%
4.19
US$2,200,372 		524,560 -21.1% 4.19 US$2,200,372
2025-12-03 2025-12-03 S Sale
2.9
Leonard Braden Michael
Large shareholder
222,925 -8.4%
4.17
US$929,597 		222,925 -8.4% 4.17 US$929,597
2025-12-03 2025-12-02 S Sale
2.9
Leonard Braden Michael
Large shareholder
51,961 -1.9%
4.20
US$218,236 		51,961 -1.9% 4.20 US$218,236
2025-12-03 2025-12-01 S Sale
2.9
Leonard Braden Michael
Large shareholder
300,000 -9.8%
4.20
US$1,260,000 		300,000 -9.8% 4.20 US$1,260,000
2025-05-16 2025-05-15 S Sale
2.9
Seyedkazemi Setareh

CHIEF DEVELOPMENT OFFICER

Officer
924 -6.3%
2.00
US$1,848 		924 -6.3% 2.00 US$1,848
2025-05-16 2025-05-15 S Sale
1.5
Fischer Laurent

CEO, PRESIDENT AND DIRECTOR

Executive Director
9,126 -9.4%
2.00
US$18,252 		9,126 -9.4% 2.00 US$18,252
2025-05-16 2025-05-15 S Sale
1.6
Soparkar Peter

CHIEF OPERATING OFFICER

Officer
2,960 -7.0%
2.00
US$5,920 		2,960 -7.0% 2.00 US$5,920
2025-04-24 2025-04-23 B Purchase
2.9
Leonard Braden Michael
Large shareholder
50,000 +35.3%
2.98
US$148,950 		50,000 +35.3% 2.98 US$148,950
2025-04-24 2025-04-22 B Purchase
2.9
Leonard Braden Michael
Large shareholder
300,000 +10.9%
3.00
US$900,000 		300,000 +10.9% 3.00 US$900,000
2025-04-02 2025-04-02 B Purchase
2.9
Leonard Braden Michael
Large shareholder
15,209 +0.6%
4.04
US$61,408 		15,209 +0.6% 4.04 US$61,408
2025-04-02 2025-03-31 B Purchase
2.9
Leonard Braden Michael
Large shareholder
19,566 +0.7%
4.38
US$85,668 		19,566 +0.7% 4.38 US$85,668
2025-04-28 2025-03-27 B Purchase
2.9
Leonard Braden Michael
Large shareholder
16,593 +13.3%
5.19
US$86,089 		16,593 +13.3% 5.19 US$86,089
2025-04-28 2025-03-26 B Purchase
2.9
Leonard Braden Michael
Large shareholder
20,407 +19.5%
5.04
US$102,841 		20,407 +19.5% 5.04 US$102,841
2025-03-27 2025-03-26 B Purchase
2.9
Leonard Braden Michael
Large shareholder
20,407 +19.5%
5.04
US$102,841 		20,407 +19.5% 5.04 US$102,841
2025-03-20 2025-03-20 B Purchase
2.9
Leonard Braden Michael
Large shareholder
30,600 +1.1%
5.61
US$171,767 		30,600 +1.1% 5.61 US$171,767
2025-03-20 2025-03-19 B Purchase
2.9
Leonard Braden Michael
Large shareholder
25,000 +0.9%
4.94
US$123,390 		25,000 +0.9% 4.94 US$123,390
2025-03-20 2025-03-18 B Purchase
2.9
Leonard Braden Michael
Large shareholder
44,341 +1.7%
4.73
US$209,618 		44,341 +1.7% 4.73 US$209,618
2025-03-20 2025-03-18 B Purchase
2.9
Leonard Braden Michael
Large shareholder
18,000 +0.7%
4.60
US$82,800 		18,000 +0.7% 4.60 US$82,800
2025-02-28 2025-02-28 B Purchase
2.9
Leonard Braden Michael
Large shareholder
85,068 +3.4%
4.60
US$391,015 		85,068 +3.4% 4.60 US$391,015
2025-02-28 2025-02-27 B Purchase
2.9
Leonard Braden Michael
Large shareholder
86,802 +3.6%
4.46
US$387,094 		86,802 +3.6% 4.46 US$387,094
2025-02-28 2025-02-26 B Purchase
2.9
Leonard Braden Michael
Large shareholder
164,886 +7.3%
4.01
US$660,979 		164,886 +7.3% 4.01 US$660,979
2024-07-31 2024-07-30 B Purchase
2.9
Leonard Braden Michael
Large shareholder
85,800 +3.9%
7.15
US$613,470 		85,800 +3.9% 7.15 US$613,470
2024-07-18 2024-07-18 B Purchase
2.9
Leonard Braden Michael
Large shareholder
80,718 +3.8%
9.11
US$735,736 		80,718 +3.8% 9.11 US$735,736
2024-07-18 2024-07-17 B Purchase
2.9
Leonard Braden Michael
Large shareholder
135,546 +6.9%
7.75
US$1,049,926 		135,546 +6.9% 7.75 US$1,049,926
2024-02-09 2024-02-07 B Purchase
1.8
Scopa James Paul
Non-Executive Director
100,000 +inf%
1.35
US$135,000 		100,000 +inf% 1.35 US$135,000
2024-02-09 2024-02-07 B Purchase
Lupher, Jr. Mark L.
Non-Executive Director
130,000 +inf%
1.35
US$175,500 		130,000 +inf% 1.35 US$175,500
2023-09-18 2023-09-15 S Sale
2.9
Seyedkazemi Setareh

Chief Development Officer

Officer
130 -0.3%
1.55
US$201 		130 -0.3% 1.55 US$201
2023-09-18 2023-09-15 PlS Planned sale
2.9
Seyedkazemi Setareh

Chief Development Officer

Officer
6,071 -11.3%
1.52
US$9,228 		6,071 -11.3% 1.52 US$9,228
2023-06-09 2023-06-07 B Purchase
2.4
Rubinstein Linda M

Chief Financial Officer

Officer
100,000 +inf%
1.45
US$145,490 		100,000 +inf% 1.45 US$145,490
2023-03-17 2023-03-15 PlS Planned sale
1.6
Soparkar Peter

Chief Operating Officer

Officer
13,360 -4.8%
0.78
US$10,442 		13,360 -4.8% 0.78 US$10,442
2023-03-17 2023-03-15 PlS Planned sale
1.5
Fischer Laurent

CEO, President and Director

Executive Director
41,239 -5.6%
0.78
US$32,232 		41,239 -5.6% 0.78 US$32,232
2023-03-17 2023-03-15 PlS Planned sale
Riley Brigit

Chief Scientific Officer

Officer
7,299 -5.9%
0.78
US$5,705 		7,299 -5.9% 0.78 US$5,705
2022-09-21 2022-09-19 PlS Planned sale
1.5
Fischer Laurent

CEO, President and Director

Executive Director
41,082 -5.3%
1.07
US$43,941 		41,082 -5.3% 1.07 US$43,941
2022-09-21 2022-09-19 PlS Planned sale
1.6
Soparkar Peter

See Remarks section

Officer
13,305 -4.6%
1.07
US$14,232 		13,305 -4.6% 1.07 US$14,232
2022-09-21 2022-09-19 PlS Planned sale
Riley Brigit

Chief Scientific Officer

Officer
7,266 -5.8%
1.07
US$7,772 		7,266 -5.8% 1.07 US$7,772
2022-09-21 2022-09-19 S Sale
2.9
Seyedkazemi Setareh

Chief Development Officer

Officer
6,058 -11.2%
1.07
US$6,480 		6,058 -11.2% 1.07 US$6,480
2022-09-21 2022-09-19 S Sale
3.1
Beckman Richard

Chief Medical Officer

Officer
4,272 -9.9%
1.07
US$4,570 		4,272 -9.9% 1.07 US$4,570
2022-05-24 2022-05-23 B Purchase
2.9
Seyedkazemi Setareh

Chief Development Officer

Officer
20,000 +3333.3%
0.84
US$16,800 		20,000 +3333.3% 0.84 US$16,800
2022-05-19 2022-05-17 B Purchase
3.1
Beckman Richard

Chief Medical Officer

Officer
10,000 +inf%
0.82
US$8,228 		10,000 +inf% 0.82 US$8,228
2022-05-17 2022-05-17 B Purchase
3.6
D'Souza Rupert

Chief Financial Officer

Officer
10,000 +92.2%
0.83
US$8,272 		10,000 +92.2% 0.83 US$8,272
2022-05-18 2022-05-16 B Purchase
3.0
Svoronos Dawn
Non-Executive Director
30,000 +150.0%
0.85
US$25,578 		30,000 +150.0% 0.85 US$25,578
2022-05-17 2022-05-13 B Purchase
3.6
D'Souza Rupert

Chief Financial Officer

Officer
10,000 +1176.5%
0.86
US$8,585 		10,000 +1176.5% 0.86 US$8,585
2022-04-22 2022-04-20 B Purchase
1.5
Fischer Laurent

CEO, President and Director

Executive Director
25,000 +3.4%
1.11
US$27,800 		25,000 +3.4% 1.11 US$27,800
2022-04-20 2022-04-19 B Purchase
1.6
Soparkar Peter

See Remarks section

Officer
21,750 +8.4%
1.14
US$24,795 		21,750 +8.4% 1.14 US$24,795
2022-04-20 2022-04-19 B Purchase
1.6
Soparkar Peter

See Remarks section

Officer
175 +0.1%
1.14
US$199 		175 +0.1% 1.14 US$199
2021-12-10 2021-12-09 B Purchase
1.5
Fischer Laurent

CEO, President and Director

Executive Director
14,323 +2.0%
1.85
US$26,498 		14,323 +2.0% 1.85 US$26,498
2021-12-10 2021-12-08 PP Planned purchase
1.5
Fischer Laurent

CEO, President and Director

Executive Director
10,677 +1.5%
1.79
US$19,112 		10,677 +1.5% 1.79 US$19,112
2021-12-10 2021-12-08 PP Planned purchase
1.6
Soparkar Peter

See Remarks section

Officer
25,000 +10.7%
1.91
US$47,750 		25,000 +10.7% 1.91 US$47,750
2021-11-17 2021-11-15 S Sale
1.8
Scopa James Paul
Non-Executive Director
50,000 -93.7%
2.18
US$109,000 		50,000 -93.7% 2.18 US$109,000
2021-10-04 2021-09-30 S Sale
2.4
Clark Julie

Chief Medical Officer

Officer
4,766 -2.8%
2.17
US$10,342 		4,766 -2.8% 2.17 US$10,342
2021-04-01 2021-03-31 B Purchase
3.0
Svoronos Dawn
Non-Executive Director
20,000 +inf%
10.02
US$200,338 		20,000 +inf% 10.02 US$200,338
2021-03-24 2021-03-24 B Purchase
1.5
Machado Patrick
Non-Executive Director
10,000 +12.8%
9.92
US$99,196 		10,000 +12.8% 9.92 US$99,196
2021-03-24 2021-03-24 B Purchase
1.5
Fischer Laurent

CEO and Director

Executive Director
10,000 +61.4%
9.88
US$98,780 		10,000 +61.4% 9.88 US$98,780
2021-02-11 2021-02-09 S Sale
3.8
PATTERSON LEONE D

President and CFO

Officer
62 -0.1%
14.14
US$877 		62 -0.1% 14.14 US$877
2021-02-11 2021-02-09 S Sale
3.8
PATTERSON LEONE D

President and CFO

Officer
12,471 -11.3%
14.10
US$175,841 		12,471 -11.3% 14.10 US$175,841
2021-01-19 2021-01-15 B Purchase
1.5
Machado Patrick
Non-Executive Director
10,000 +14.7%
11.52
US$115,174 		10,000 +14.7% 11.52 US$115,174
2021-01-19 2021-01-15 B Purchase
1.5
Fischer Laurent

CEO and Director

Executive Director
8,600 +111.8%
11.53
US$99,191 		8,600 +111.8% 11.53 US$99,191
2020-08-19 2020-08-17 PP Planned purchase
1.6
Soparkar Peter

Chief Legal Officer

Officer
7,692 +256.4%
13.00
US$99,996 		7,692 +256.4% 13.00 US$99,996
2020-08-19 2020-08-17 B Purchase
1.5
Fischer Laurent

CEO and Director

Executive Director
7,692 +inf%
13.00
US$99,996 		7,692 +inf% 13.00 US$99,996
2020-07-22 2020-07-20 PlS Planned sale
Gasmi Mehdi
Non-Executive Director
5,000 -1.8%
17.60
US$87,978 		5,000 -1.8% 17.60 US$87,978
2020-06-23 2020-06-22 PlS Planned sale
Gasmi Mehdi
Non-Executive Director
23,605 -7.9%
25.06
US$591,617 		23,605 -7.9% 25.06 US$591,617
2020-06-18 2020-06-18 PlS Planned sale
Gasmi Mehdi
Non-Executive Director
11,127 -3.9%
25.01
US$278,329 		11,127 -3.9% 25.01 US$278,329
2020-06-18 2020-06-17 PlS Planned sale
Gasmi Mehdi
Non-Executive Director
268 -0.1%
25.01
US$6,703 		268 -0.1% 25.01 US$6,703
2020-06-17 2020-06-16 S Sale
3.8
PATTERSON LEONE D

President

Officer
13,171 -10.7%
24.68
US$325,060 		13,171 -10.7% 24.68 US$325,060
2020-06-17 2020-06-15 PlS Planned sale
Gasmi Mehdi
Non-Executive Director
159 -0.1%
23.59
US$3,751 		159 -0.1% 23.59 US$3,751
2020-06-17 2020-06-15 PlS Planned sale
Gasmi Mehdi
Non-Executive Director
3,425 -1.2%
23.00
US$78,787 		3,425 -1.2% 23.00 US$78,787
2020-06-17 2020-06-15 PlS Planned sale
Gasmi Mehdi
Non-Executive Director
1,416 -0.5%
21.93
US$31,047 		1,416 -0.5% 21.93 US$31,047
2020-06-17 2020-06-15 PlS Planned sale
Gasmi Mehdi
Non-Executive Director
5,000 -1.8%
21.01
US$105,042 		5,000 -1.8% 21.01 US$105,042
2020-05-22 2020-05-20 PlS Planned sale
Gasmi Mehdi
Non-Executive Director
1,401 -0.5%
20.01
US$28,030 		1,401 -0.5% 20.01 US$28,030
2020-05-20 2020-05-18 PlS Planned sale
Gasmi Mehdi
Non-Executive Director
300 -0.1%
19.03
US$5,709 		300 -0.1% 19.03 US$5,709
2020-05-20 2020-05-18 PlS Planned sale
Gasmi Mehdi
Non-Executive Director
4,700 -1.7%
18.11
US$85,124 		4,700 -1.7% 18.11 US$85,124
2020-05-20 2020-05-06 PlS Planned sale
Gasmi Mehdi
Non-Executive Director
25,000 -8.3%
20.03
US$500,668 		25,000 -8.3% 20.03 US$500,668
Explore more

More insider trading research around Adverum Biotechnologies Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America